A Single-Dose Study of LY3471851 in Healthy Participants

Nektar Therapeutics

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3471851

Study type

Interventional

Funder types

Industry

Identifiers

NCT04998487

17604

J1P-MC-KFAL (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it when administered under the skin in healthy participants. The study will also evaluate the safety and tolerability of LY3471851. The study is expected to last up to 87 days for each participant.

Enrollment

71 patients

Sex

All

Ages

18 to 64 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly healthy males or females, as determined by medical history and physical examination.
Body weight greater than 55 kilograms (kg) and body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²)

Exclusion criteria

Have evidence of clinically significant active infection, including fever 100.5ºF (38ºC) or above, within 28 days of dosing or Day 1 (before dosing)
Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening. Examples include but are not limited to infections requiring intravenous antibiotics, hospitalization, or prolonged treatment
Are immunocompromised per investigator judgment.